OnKure Therapeutics reported revenue of $1.55M and net income of -$16.90M for the quarter ended Jun 2026, up 66.3% year over year. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||
| Revenue | 0.20M | -0.04M | 1.20M | 1.08M | 0.93M | 0.80M | 0.62M | 0.46M | 1.55M | |||||||||||||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 9.32M | 7.10M | 9.28M | 8.13M | 9.94M | 10.36M | 10.99M | 14.40M | 13.62M | -6.89M | 8.57M | 10.75M | 10.12M | 14.36M | 13.01M | 12.61M | 11.92M | 10.72M | 11.71M | 12.61M | ||||||
| Share-based Compensation (IS)Stock Comp. | 0.11M | 2.75M | ||||||||||||||||||||||||
| Selling, General & AdministrativeSG&A | 3.43M | 3.52M | 3.74M | 4.30M | 3.90M | 4.21M | 5.13M | 6.64M | 7.27M | -14.22M | 1.27M | 3.59M | 1.40M | 4.34M | 3.99M | 3.71M | 3.59M | 3.41M | 3.91M | 4.29M | ||||||
| Operating ExpensesOpex | 12.75M | 10.62M | 13.02M | 12.43M | 13.84M | 14.56M | 16.12M | 21.04M | 20.89M | -21.11M | 9.83M | 14.34M | 11.51M | 18.70M | 17.00M | 16.32M | 15.50M | 14.13M | 15.62M | 16.90M | ||||||
| Operating IncomeOp. Inc | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.83M | -14.34M | -11.51M | -18.70M | -17.00M | -16.32M | -15.50M | -14.13M | -15.62M | -16.90M | ||||||
| EBIT | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.83M | -14.34M | -11.51M | -18.70M | -17.00M | -16.32M | -15.50M | -14.13M | -15.62M | -16.90M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.03M | 0.22M | 0.06M | 0.00M | 0.01M | |||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.02M | 0.02M | -0.02M | 0.12M | 0.83M | 0.96M | 1.02M | 1.51M | 1.69M | 1.45M | 1.14M | 1.00M | 0.97M | |||||||||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.83M | -14.37M | -11.73M | -18.76M | -17.00M | -16.32M | -15.50M | -14.13M | -15.62M | -16.90M | ||||||
| Profit After TaxPAT | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.83M | -14.37M | -11.73M | -18.76M | -17.00M | -16.32M | -15.50M | -14.13M | -15.62M | -16.90M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.83M | -14.37M | -11.73M | -18.76M | -17.00M | -16.32M | -15.50M | -14.13M | -15.62M | -16.90M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -12.75M | -10.62M | -13.02M | -12.43M | -13.84M | -14.56M | -16.12M | -21.04M | -20.89M | 21.11M | -9.83M | -14.37M | -11.73M | -18.76M | -17.00M | -16.32M | -15.50M | -14.13M | -15.62M | -16.90M | ||||||
| Income towards Parent CompanyParent Net Inc | -12.74M | -10.61M | -13.04M | -12.31M | -13.01M | -13.60M | -15.11M | -19.53M | -19.20M | 18.52M | -9.54M | -14.14M | -11.56M | -17.44M | -15.93M | -15.39M | -14.70M | -13.50M | -15.16M | -15.35M | ||||||
| Net Income towards Common StockholdersNet Income | -12.74M | -10.61M | -13.04M | -12.31M | -13.01M | -13.60M | -15.11M | -19.53M | -19.20M | 18.52M | -9.54M | -14.14M | -11.56M | -17.44M | -15.93M | -15.39M | -14.70M | -13.50M | -15.16M | -15.35M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -5.22 | -5.85 | -5.33 | -5.03 | -5.31 | -5.55 | -6.03 | -6.46 | -5.68 | 6.04 | -2.85 | -4.23 | -3.46 | -5.06 | -1.19 | -1.14 | -1.09 | -1.00 | -1.11 | -0.31 | ||||||
| EPS (Diluted) | -5.22 | -5.85 | -5.33 | -5.03 | -5.31 | -5.55 | -6.03 | -6.46 | -5.68 | 6.04 | -2.85 | -4.23 | -3.46 | -5.06 | -1.19 | -1.14 | -1.09 | -1.00 | -1.11 | -0.31 | ||||||
| Shares Outstanding | 2.44M | 1.81M | 2.45M | 2.45M | 2.45M | 2.45M | 2.50M | 3.02M | 3.38M | 3.07M | 3.34M | 3.34M | 3.34M | 3.45M | 13.42M | 13.51M | 13.53M | 13.52M | 13.67M | 49.87M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 2.44M | 1.81M | 2.45M | 2.45M | 2.45M | 2.45M | 2.50M | 3.02M | 3.38M | 3.07M | 3.34M | 3.34M | 3.34M | 3.45M | 13.42M | 13.51M | 13.53M | 13.52M | 13.67M | 49.87M | ||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 2.44M | 1.81M | 2.45M | 2.45M | 2.45M | 2.47M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.35M | 12.76M | 12.84M | 12.86M | 13.67M | 13.67M | 40.50M | ||||||
| EBITDA | -12.74M | -10.61M | -13.00M | -12.41M | -13.82M | -14.54M | -16.08M | -21.00M | -20.85M | 21.40M | -9.72M | -14.23M | -11.27M | -18.57M | -16.88M | -16.21M | -15.39M | -14.02M | -15.51M | -16.81M | ||||||
| Interest ExpensesInt Expense | 0.03M | 0.22M | 0.06M | 0.00M | 0.01M |
Pull OnKure Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=OKUR&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "OKUR", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=OKUR&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();